EBOOK

Autoantibodies


€ 180,99
 
epub eBook
Sofort lieferbar (Download)
Oktober 2011

Beschreibung

Beschreibung

Autoantibodies was published and presented in November 2006 at the International Congress of Autoimmunity in Sorrento, a small town in Campania, Italy. The Congress also celebrated the 100th anniversary of the first routine test for autoantibodies. An autoantibody is a type of antibody that is produced by the immune system and that fights one or more of a person's own proteins. These autoantibodies cause autoimmune diseases such as lupus erythematosus. The authors and editors of this book provide a critical review of autoantibodies and their primary functions. They cite a number of major developments in the field of autoantibodies, including the detection of autoantibodies in which a healthy person is a carrier; the discovery that autoantibodies can be both pathogenic and protective in some cases; and the development of a device that will help monitor and detect a specific autoantibody using a small amount of serum and proteomic arrays. Aside from the pathogenic and protective autoantibodies, the book also discusses irrelevant autoantibodies, as these may be relevant for future research. It also addresses the importance of the autoantibodies in a person's body. Clinical physicians, as well as scientists interested in the significance of autoantibodies in the human body, will find this book relevant. It will also be of interest to those who suffer from an autoimmune disease.* Incudes and exhaustive list of autoantibodies not covered by other publications* Short reviews can easily be checked for quick reference information* Both basic and clinical aspects are covered

Inhaltsverzeichnis

1;Title Page;4 2;Copyright Page;5 3;Table of Contents;8 4;Foreword;16 5;Preface;20 6;About the Editors;22 7;List of Contributors;24 8;Introduction;34 9;Part I Introduction: Autoantibodies-Unique Characteristics;36 9.1;Chapter 1 What is an Autoantibody?;38 9.1.1;Abstract;38 9.1.2;Introduction;38 9.1.3;Characterization of autoimmune diseases;39 9.1.4;Tolerance;39 9.1.5;Concluding remarks;40 9.1.6;References;40 9.2;Chapter 2 Natural Autoantibodies, Heralding, Protecting and Inducing Autoimmunity;42 9.2.1;Abstract;42 9.2.2;Historical notes;42 9.2.3;The origin of NAbs;43 9.2.4;NAbs and autoimmunity;44 9.2.5;NAbs and the innate immune system;44 9.2.6;Apoptosis and NAbs;45 9.2.7;Protective NAbs;45 9.2.8;References;47 9.3;Chapter 3 Molecular Mimicry;48 9.3.1;Abstract;48 9.3.2;Historical notes;48 9.3.3;Forms of molecular mimicry;49 9.3.4;Natural autoantibodies and molecular mimicry;51 9.3.5;Animal model of molecular mimicry;52 9.3.6;Clinical utility;52 9.3.7;Conclusion;53 9.3.8;References;54 9.4;Chapter 4 Affinity and Avidity of Autoantibodies;56 9.4.1;Abstract;56 9.4.2;Historical notes;56 9.4.3;Avidity and affinity;57 9.4.4;Clinical utility in autoimmune disorders;61 9.4.5;Take-home messages;62 9.4.6;References;63 9.5;Chapter 5 Pathogenic Mechanisms and Clinical Relevance of Autoantibodies;64 9.5.1;Abstract;64 9.5.2;Introduction;64 9.5.3;Cell surface binding and lysis (cytotoxicity);65 9.5.4;Binding to cell surface receptors without cytolysis;66 9.5.5;Immune complexmediated damage;67 9.5.6;Translocation of intracellular antigens to cell membrane;68 9.5.7;Penetration into living cells;69 9.5.8;Binding to extracellular molecules;69 9.5.9;Take-home messages;70 9.5.10;References;70 9.6;Chapter 6 Native Autoantigens Versus Recombinant Autoantigens;72 9.6.1;Abstract;72 9.6.2;Introduction;72 9.6.3;Detection of autoantibodies;73 9.6.4;ELISA;73 9.6.5;Native autoantigens;75 9.6.6;Recombinant autoantigens;76 9.6.7;Criteria for usage of autoantigens in immunoassays;78 9.6.8;Limitations
of recombinant technology for the production of autoantigens;79 9.6.9;Acknowledgements;79 9.6.10;Take-home messages;79 9.6.11;References;79 9.7;Chapter 7 Redox-Reactive Autoantibodies;82 9.7.1;Abstract;82 9.7.2;Historical notes;83 9.7.3;Autoantigens;83 9.7.4;Autoantibodies;84 9.7.5;Acknowledgements;87 9.7.6;Take-home messages;87 9.7.7;References;87 9.8;Chapter 8 Predictive Autoantibodies;90 9.8.1;Abstract;90 9.8.2;Introduction;90 9.8.3;Prediction of disease;91 9.8.4;Prediction of specific clinical manifestations;91 9.8.5;Hierarchy of autoantibodies;92 9.8.6;Combining HLA and predictive antibodies in prediction;93 9.8.7;Combining specific genes and antibody testing;93 9.8.8;Implications and future directions;93 9.8.9;Take-home messages;95 9.8.10;References;95 9.9;Chapter 9 Autoantibody Subclasses;96 9.9.1;Abstract;96 9.9.2;Historical notes;96 9.9.3;The findings;97 9.9.4;The methods;100 9.9.5;The causes;100 9.9.6;The consequences;101 9.9.7;Conclusion;101 9.9.8;References;102 9.10;Chapter 10 Idiotypes and Anti-Idiotypes;104 9.10.1;Abstract;104 9.10.2;Historical notes;105 9.10.3;The autoantigen(s);105 9.10.4;Structure of idiotypes;106 9.10.5;Genetics;106 9.10.6;Autoantibodies;106 9.10.7;Physiologic role;107 9.10.8;Pathogenic role;107 9.10.9;Clinical utility;109 9.10.10;Summary;110 9.10.11;Take-home messages;110 9.10.12;References;111 9.11;Chapter 11 Novel Diagnostic Methods for Autoantibody Detection;112 9.11.1;Abstract;112 9.11.2;The use of single autoantibody tests in the diagnosis and classification of autoimmune diseases: The old technologies;113 9.11.3;Multiplex technologies for the study of autoantibody profiles: The new technologies;113 9.11.4;The predictive role of autoantibody profiles;116 9.11.5;Take-home messages;116 9.11.6;References;117 10;Part II Allergic Disease Autoantibodies;118 10.1;Chapter 12 Human IgESpecific Autoantibodies and Autoantibodies to IgE Receptors;120 10.1.1;Summary;120 10.1.2;Human IgE;121 10.1.3;IgE receptors;124 10.1.4;Antibodies to I
gE receptors;125 10.1.5;Take-home messages;126 10.1.6;References;126 11;Part III Antineutrophil Antibodies;128 11.1;Chapter 13 Antineutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase;130 11.1.1;Abstract;130 11.1.2;Historical notes;131 11.1.3;The autoantigen;131 11.1.4;The autoantibodies;133 11.1.5;Clinical utility;135 11.1.6;Take-home messages;137 11.1.7;References;137 11.2;Chapter 14 Antineutrophil Cytoplasmic Autoantibodies with Specificity for Proteinase 3;140 11.2.1;Abstract;140 11.2.2;Historical notes;141 11.2.3;Autoantigen;141 11.2.4;Autoantibody;142 11.2.5;Clinical utility;143 11.2.6;Take-home messages;144 11.2.7;References;144 11.3;Chapter 15 Neutrophil-Specific Antinuclear and Anti-cytoplasmic Antibodies in Chronic Inflammatory Diseases;146 11.3.1;Abstract;146 11.3.2;Historical notes;147 11.3.3;Autoantigens;147 11.3.4;Autoantibody;148 11.3.5;Clinical utility and prognostic value;149 11.3.6;Conclusions;151 11.3.7;References;151 11.4;Chapter 16 Antineutrophil Cytoplasmatic Autoantibodies with Specificity to Proteinase 3;154 11.4.1;Abstract;154 11.4.2;Historical notes;155 11.4.3;Autoantigens;155 11.4.4;The autoantibodies;156 11.4.5;Clinical utility;159 11.4.6;Take-home messages;161 11.4.7;References;161 12;Part IV Introduction: Antinuclear Antibodies;162 12.1;Chapter 17 Antinuclear Antibodies: General Introduction;164 12.1.1;Abstract;164 12.1.2;Historical notes;164 12.1.3;Autoantigens;165 12.1.4;Autoantibodies;165 12.1.5;Take-home messages;167 12.1.6;References;168 12.2;Chapter 18 Antinucleolar Antibodies;170 12.2.1;Abstract;170 12.2.2;Historical notes;170 12.2.3;Autoantigen;171 12.2.4;Autoantibodies;171 12.2.5;Conclusion;173 12.2.6;Take-home messages;174 12.2.7;References;174 12.3;Chapter 19 Anti-Chromatin (Nucleosome) Autoantibodies;176 12.3.1;Abstract;176 12.3.2;Historical notes;177 12.3.3;Autoantigen;177 12.3.4;Autoantibody;178 12.3.5;Clinical utility;180 12.3.6;Conclusion;183 12.3.7;Take-home messages;183 12.3.8;References;183 12.4;
Chapter 20 Centromere Autoantibodies;186 12.4.1;Abstract;186 12.4.2;Historical notes;186 12.4.3;Autoantigen;187 12.4.4;Autoantibody;189 12.4.5;Methods of detection;190 12.4.6;Clinical utility;190 12.4.7;Take-home messages;192 12.4.8;References;192 12.5;Chapter 21 dsDNA Autoantibodies;194 12.5.1;Abstract;194 12.5.2;Historical notes;195 12.5.3;Autoantigen;195 12.5.4;Autoantibody;196 12.5.5;Clinical utility;199 12.5.6;References;202 12.6;Chapter 22 Histone Autoantibodies;204 12.6.1;Abstract;204 12.6.2;Historical notes;204 12.6.3;The autoantigens;205 12.6.4;Autoantibodies;208 12.6.5;Clinical utility;210 12.6.6;Take-home messages;211 12.6.7;References;211 12.7;Chapter 23 Ku and Ki Autoantibodies;212 12.7.1;Summary;212 12.7.2;Historical notes;212 12.7.3;Autoantigens;213 12.7.4;Autoantibodies;215 12.7.5;Clinical utility;216 12.7.6;Take-home messages;219 12.7.7;References;219 12.8;Chapter 24 Neuronal Nuclear Autoantibodies, Type 1 (Hu);220 12.8.1;Abstract;220 12.8.2;Historical notes;221 12.8.3;Autoantigens;221 12.8.4;Autoantibody;222 12.8.5;Clinical utility;223 12.8.6;Take-home messages;225 12.8.7;References;225 12.9;Chapter 25 Nuclear Envelope Protein Autoantibodies/Antilamin Autoantibodies;226 12.9.1;Summary;226 12.9.2;Historical notes;227 12.9.3;Autoantigens;227 12.9.4;Autoantibody;229 12.9.5;Take-home messages;230 12.9.6;References;230 12.10;Chapter 26 Anti-Nucleosome Autoantibodies;232 12.10.1;Abstract;232 12.10.2;Historical notes;233 12.10.3;Autoantigen;233 12.10.4;Autoantibody;234 12.10.5;Clinical utility;236 12.10.6;Take-home messages;238 12.10.7;References;238 12.11;Chapter 27 Proliferating Cell Nuclear Antigen Autoantibodies;240 12.11.1;Historical notes;240 12.11.2;Autoantigens;241 12.11.3;Autoantibodies;242 12.11.4;Clinical utility;243 12.11.5;Conclusion;245 12.11.6;Acknowledgements;245 12.11.7;References;245 12.12;Chapter 28 Anti-RA33 Antibodies (Antibodies to the Heterogeneous Nuclear Ribonucleoprotein A2);246 12.12.1;Abstract;246 12.12.2;Historical notes;247 1
2.12.3;Autoantigen;247 12.12.4;Autoantibody;248 12.12.5;Clinical utility;249 12.12.6;Take-home messages;250 12.12.7;References;250 12.13;Chapter 29 Anti-Ribosomal P Antibodies;252 12.13.1;Abstract;252 12.13.2;Autoantigen;252 12.13.3;Autoantibody;253 12.13.4;Assays for anti-rib-P Ab detection;254 12.13.5;Serological test performance;256 12.13.6;Clinical studies;256 12.13.7;Conclusion;257 12.13.8;Take-home messages;257 12.13.9;References;257 12.14;Chapter 30 SS-A (Ro) Autoantibodies;260 12.14.1;Historical notes;260 12.14.2;Autoantigen;260 12.14.3;Autoantibodies;262 12.14.4;Clinical utility;264 12.14.5;Conclusion;264 12.14.6;References;265 12.15;Chapter 31 Topoisomerase-I (Scl-70) Autoantibodies;266 12.15.1;Abstract;266 12.15.2;Historical notes;267 12.15.3;Autoantigen;267 12.15.4;Autoantibody;268 12.15.5;Clinical utility;271 12.15.6;Take-home messages;272 12.15.7;References;272 12.16;Chapter 32 SS-B (La) Autoantibodies;274 12.16.1;Abstract;274 12.16.2;Historical notes;274 12.16.3;Autoantigen;275 12.16.4;Autoantibody;277 12.16.5;Clinical utility;279 12.16.6;Take-home messages;280 12.16.7;References;281 12.17;Chapter 33 Anti-RNA Polymerase III Antibodies;282 12.17.1;Abstract;282 12.17.2;Historical notes;283 12.17.3;Autoantigen(s);283 12.17.4;Autoantibody;285 12.17.5;Clinical utility;287 12.17.6;Take-home messages;289 12.17.7;References;289 13;Part V Autoantibodies to Biologic Factors/Structures;290 13.1;Chapter 34 GW Bodies, P Bodies and Components of the miRNA Pathway;292 13.1.1;Abstract;292 13.1.2;Historical notes;292 13.1.3;Autoantigen;293 13.1.4;Autoantibody;295 13.1.5;Clinical utility;295 13.1.6;Take-home messages;296 13.1.7;References;297 13.2;Chapter 35 Golgi Complex and Endosome Antibodies;298 13.2.1;Abstract;298 13.2.2;Autoantigen;298 13.2.3;Autoantibody;301 13.2.4;Clinical utility;303 13.2.5;Take-home messages;305 13.2.6;References;305 13.3;Chapter 36 p53 Autoantibodies;306 13.3.1;Abstract;306 13.3.2;Historical notes;306 13.3.3;Autoantigen;307 13.3.4;Autoantibo
dy;309 13.3.5;Clinical utility;310 13.3.6;Take-home messages;311 13.3.7;References;311 13.4;Chapter 37 Human Antiganglioside Autoantibodies;312 13.4.1;Abstract;312 13.4.2;Historical notes;313 13.4.3;Autoantigens;313 13.4.4;Autoantibody;314 13.4.5;Clinical utility;316 13.4.6;Take-home messages;318 13.4.7;Acknowledgement;318 13.4.8;References;318 13.5;Chapter 38 Human Anti-alpha-Galactosyl Antibodies;320 13.5.1;Abstract;320 13.5.2;Historical notes;321 13.5.3;Autoantigen;321 13.5.4;Autoantibody;322 13.5.5;Clinical utility;323 13.5.6;Take-home messages;325 13.5.7;References;325 13.6;Chapter 39 Autoantibodies in Therapeutic Preparations of Human Intravenous Immunoglobulin (IVIG);328 13.6.1;Abstract;328 13.6.2;Historical notes;329 13.6.3;Autoantigens;329 13.6.4;Autoantibodies;329 13.6.5;Clinical utility;331 13.6.6;Take-home messages;332 13.6.7;References;332 13.7;Chapter 40 Cytokine Antibodies;334 13.7.1;Abstract;334 13.7.2;Historical notes;335 13.7.3;The autoantigens;336 13.7.4;The autoantibodies;338 13.7.5;Clinical utility;340 13.7.6;Take-home messages;342 13.7.7;Acknowledgement;342 13.7.8;References;342 13.8;Chapter 41 Cytoskeletal Autoantibodies/Anti-Actin Antibodies;344 13.8.1;Abstract;344 13.8.2;Historical notes;344 13.8.3;The autoantigen;345 13.8.4;Autoantibody;346 13.8.5;Clinical utility;350 13.8.6;Take-home messages;350 13.8.7;References;351 13.9;Chapter 42 Fibrillarin Autoantibodies;352 13.9.1;Abstract;352 13.9.2;Historical notes;352 13.9.3;Autoantigen;353 13.9.4;Autoantibody;354 13.9.5;Clinical utility;356 13.9.6;Take-home messages;358 13.9.7;Acknowledgements;358 13.9.8;References;358 13.10;Chapter 43 Fibronectin Autoantibodies;360 13.10.1;Abstract;360 13.10.2;Historical notes;360 13.10.3;Autoantigen;361 13.10.4;Autoantibody;362 13.10.5;Clinical utility;363 13.10.6;Take-home messages;364 13.10.7;References;364 13.11;Chapter 44 Interferon-Inducible Protein IFI16 Autoantibodies;366 13.11.1;Abstract;366 13.11.2;Historical notes;366 13.11.3;Autoantigen;367 13.11.4;
Autoantibodies;369 13.11.5;Clinical utility;370 13.11.6;Take-home messages;371 13.11.7;References;371 14;Part VI Cardiac Autoantibodies;374 14.1;Chapter 45 Autoantibodies in Atherosclerosis;376 14.1.1;Abstract;376 14.1.2;Introduction;377 14.1.3;Oxidized LDL and antibodies to oxidized LDL;377 14.1.4;Phosphorylcholine and anti-phosphorylcholine antibodies;379 14.1.5;Phospholipids and antiphospholipid antibodies;380 14.1.6;Take-home messages;381 14.1.7;References;381 14.2;Chapter 46 Heat Shock Protein Autoantibodies;384 14.2.1;Abstract;384 14.2.2;Historical notes and the autoimmune hypothesis of atherogenesis;384 14.2.3;Autoantigen;385 14.2.4;Take-home messages;388 14.2.5;References;388 14.3;Chapter 47 Myocardial Autoantibodies and their Clinical Significance;390 14.3.1;Abstract;390 14.3.2;Historical and general perspective;391 14.3.3;Infectious agents implicated in human DCM;393 14.3.4;Autoantigens identified in sera of IDCM patients;395 14.3.5;Immunogobulin apheresis as a therapeutic option in DCM;397 14.3.6;Clinical relevance of cardiac specific autoantibodies in human DCM;397 14.3.7;Take-home messages;399 14.3.8;References;399 15;Part VII Endocrine Autoantibodies;402 15.1;Chapter 48 Glutamic Acid Decarboxylase Autoantibodies;404 15.1.1;Abstract;404 15.1.2;Historical notes;405 15.1.3;Autoantigen;405 15.1.4;Autoantibody;407 15.1.5;Clinical utility;409 15.1.6;Take-home messages;413 15.1.7;References;413 15.2;Chapter 49 Humoral Immunity in Type 1 Diabetes Mellitus;414 15.2.1;Abstract;414 15.2.2;Historical notes;415 15.2.3;Autoantigen;415 15.2.4;Autoantibody;418 15.2.5;Clinical utility;421 15.2.6;Take-home messages;422 15.2.7;References;422 15.3;Chapter 50 Antibodies to Adrenal, Gonadal Tissues and Steroidogenic Enzymes;424 15.3.1;Abstract;424 15.3.2;Historical notes;425 15.3.3;Adrenal and gonadal autoantigens;425 15.3.4;Autoantibodies to adrenal cortex and to 21-OH;428 15.3.5;Autoantibodies to gonadal tissue and steroidogenic enzymes (17alpha-OHAbs and P450sccAbs);432
15.3.6;Take-home messages;434 15.3.7;Acknowledgements;435 15.3.8;References;435 15.4;Chapter 51 Thyroglobulin, Thyroperoxidase, and Thyrotropin-Receptor Autoantibodies;438 15.4.1;Historical notes;438 15.4.2;Thyroglobulin antibodies;439 15.4.3;Thyroperoxidase antibodies;442 15.4.4;Clinical utility;443 15.4.5;Thyrotropin-receptor antibodies;445 15.4.6;Take-home messages;448 15.4.7;References;448 16;Part VIII GI and Liver Autoantibodies;450 16.1;Chapter 52 Anti-Intestinal Goblet Cell Antibodies;452 16.1.1;Summary;452 16.1.2;Historical notes;452 16.1.3;Autoantigen;454 16.1.4;Autoantibody;454 16.1.5;Clinical utility;455 16.1.6;Take-home messages;457 16.1.7;References;457 16.2;Chapter 53 Tumor-Associated Autoantibodies;458 16.2.1;Summary;458 16.2.2;Historical notes;459 16.2.3;Autoantigenic targets of tumor-associated AAB;459 16.2.4;Relevance of tumor-associated AAB;466 16.2.5;Tumor-associated AAB Biomarkers for the prediction and early diagnosis of cancer?;467 16.2.6;Take-home messages;469 16.2.7;References;469 16.3;Chapter 54 Cryoglobulins and Cryoglobulins Secondary to Hepatitis C Virus Infection;472 16.3.1;Abstract;472 16.3.2;Historical notes;472 16.3.3;Cryoprecipitation;473 16.3.4;Autoantigen;473 16.3.5;Autoantibody;474 16.3.6;Methods of detection;475 16.3.7;Prevalence/prognosis;475 16.3.8;Treatment;475 16.3.9;Take-home messages;476 16.3.10;References;476 16.4;Chapter 55 Anti-Tissue Transglutaminase and Anti-Endomyisial Antibodies;478 16.4.1;Abstract;478 16.4.2;Historical notes;479 16.4.3;Autoantigen;479 16.4.4;Autoantibody;480 16.4.5;Clinical utility;482 16.4.6;Take-home messages;485 16.4.7;References;485 16.5;Chapter 56 Anti-Gliadin Antibodies;486 16.5.1;Abstract;486 16.5.2;Historical notes;486 16.5.3;The antigen;487 16.5.4;The antibody;488 16.5.5;Clinical utility;489 16.5.6;Take-home messages;491 16.5.7;References;491 16.6;Chapter 57 Reticulin Autoantibodies;492 16.6.1;Abstract;492 16.6.2;Historical notes;492 16.6.3;Autoantigen;493 16.6.4;Autoantibody;494 16.6.5;Cl
inical utility;496 16.6.6;Take-home messages;496 16.6.7;References;497 16.7;Chapter 58 Liver Cytosol Antigen Type 1 Autoantibodies, Liver Kidney Microsomal Autoantibodies, and Liver Microsomal Autoantibodies;498 16.7.1;Abstract;498 16.7.2;Liver kidney microsomal autoantibodies and liver microsomal autoantibodies;499 16.7.3;Autoantigen and autoantibody definitions of LKM/LM autoantibodies;499 16.7.4;Hepatitis D-associated microsomal autoantibodies;503 16.7.5;Microsomal autoantibodies in autoimmune hepatitis associated with the autoimmune polyglandular syndrome;503 16.7.6;Microsomal autoantibodies and drug reactions;504 16.7.7;Microsomal autoantibodies of unknown relevance;504 16.7.8;General role of anti-microsomal autoantibodies;504 16.7.9;Liver cytosolic autoantibodies;505 16.7.10;Autoantibody definition and autoantigen;505 16.7.11;Clinical utility;505 16.7.12;Take-home messages;505 16.7.13;References;506 16.8;Chapter 59 Antimitochondrial Antibodies;508 16.8.1;Summary;508 16.8.2;Historical notes;508 16.8.3;Autoantigens;509 16.8.4;Autoantibody;509 16.8.5;Clinical utility;510 16.8.6;Take-home messages;511 16.8.7;References;511 16.9;Chapter 60 Parietal Cell and Intrinsic Factor Autoantibodies;514 16.9.1;Summary;514 16.9.2;Historical notes;515 16.9.3;Gastric parietal cell autoantigen;515 16.9.4;Gastric parietal cell autoantibody;516 16.9.5;Intrinsic factor autoantigen;516 16.9.6;Intrinsic factor autoantibody;517 16.9.7;Clinical utility;517 16.9.8;Parietal cell antibody;517 16.9.9;Intrinsic factor antibody;518 16.9.10;Take-home messages;520 16.9.11;References;521 16.10;Chapter 61 Smooth Muscle Antibodies;522 16.10.1;Abstract;522 16.10.2;Historical notes;522 16.10.3;Autoantigen;523 16.10.4;Autoantibody;523 16.10.5;Clinical utility;524 16.10.6;References;525 17;Part IX Hematologic Autoantibodies;528 17.1;Chapter 62 Coagulation Factor Autoantibodies;530 17.1.1;Abstract;530 17.1.2;Coagulation pathways;530 17.1.3;Historical notes: Autoantibodies to coagulation factor VIII (FV
III);531 17.1.4;Autoantigen;531 17.1.5;Autoantibody;533 17.1.6;Clinical utility;535 17.1.7;Autoantibodies to other coagulation factors;537 17.1.8;Autoantibodies to von Willebrand factor autoantigen;537 17.1.9;Take-home messages;545 17.1.10;References;545 17.2;Chapter 63 Autoantibodies in Heparin-Induced Thrombocytopenia;546 17.2.1;Abstract;546 17.2.2;Historical notes;547 17.2.3;Autoantigen: The heparinplatelet factor 4 complex;547 17.2.4;Autoantibody;549 17.2.5;Clinical utility;551 17.2.6;Take-home messages;553 17.2.7;References;553 17.3;Chapter 64 Platelet Autoantibodies;556 17.3.1;Abstract;556 17.3.2;Historical notes;557 17.3.3;Platelet autoantigens;557 17.3.4;ITP;557 17.3.5;Platelet autoantibodies;559 17.3.6;Clinical utility;560 17.3.7;Take-home messages;561 17.3.8;References;561 17.4;Chapter 65 Red Cell Autoantibodies;564 17.4.1;Abstract;564 17.4.2;Introduction;565 17.4.3;Autoantigen;565 17.4.4;Clinical utility;568 17.4.5;Take-home messages;569 17.4.6;Acknowledgment;570 17.4.7;References;570 17.5;Chapter 66 Lymphocytotoxic Autoantibodies;572 17.5.1;Abstract;572 17.5.2;Historical notes;573 17.5.3;The autoantigen;573 17.5.4;The autoantibodies;575 17.5.5;Clinical utility;577 17.5.6;Clinical parameters;577 17.5.7;Take-home messages;578 17.5.8;References;578 18;Part X Kidney Autoantibodies;580 18.1;Chapter 67 Anti-ATP Synthase Beta-Chain Autoantibodies;582 18.1.1;Abstract;582 18.1.2;Historical notes;582 18.1.3;Autoantigen;583 18.1.4;Autoantibody;583 18.1.5;Clinical utility;585 18.1.6;Take-home messages;587 18.1.7;References;587 18.2;Chapter 68 Glomerular Basement Membrane Autoantibodies;588 18.2.1;Abstract;588 18.2.2;Historical notes;588 18.2.3;Autoantigen;589 18.2.4;Autoantibody;590 18.2.5;Clinical utility;592 18.2.6;Take-home messages;593 18.2.7;References;594 18.3;Chapter 69 Nephritic Factor Autoantibodies;596 18.3.1;Historical notes;596 18.3.2;The autoantigen;597 18.3.3;Autoantibodies;597 18.3.4;Clinical utility;599 18.3.5;Take-home messages;600 18.3.6;References
;600 19;Part XI Neurological System Autoantibodies;602 19.1;Chapter 70 Acetylcholine Receptor and Muscle Specific Kinase Autoantibodies;604 19.1.1;Abstract;604 19.1.2;Historical notes;604 19.1.3;The autoantigen;605 19.1.4;The autoantibody;606 19.1.5;Clinical utility;608 19.1.6;Muscle specific kinase;610 19.1.7;Conclusion;610 19.1.8;References;611 19.2;Chapter 71 Myositis Autoantibodies: Aminoacyl-tRNA Synthetase, Signal Recognition Particle, Mi-2, and PM-Scl Autoantibodies;612 19.2.1;Abstract;612 19.2.2;Historical notes;613 19.2.3;Autoantigen;616 19.2.4;Autoantibodies;619 19.2.5;Clinical utility;621 19.2.6;Take-home messages;623 19.2.7;References;623 19.3;Chapter 72 Anti-MOG Antibodies;626 19.3.1;Abstract;626 19.3.2;Historical notes;627 19.3.3;Autoantigen;627 19.3.4;Autoantibody;629 19.3.5;Clinical utility;632 19.3.6;Prognostic value;632 19.3.7;Take-home messages;633 19.3.8;References;633 19.4;Chapter 73 Antibodies to Hsp 70 in Inner Ear Disease;634 19.4.1;Abstract;634 19.4.2;Historical notes;634 19.4.3;Autoantigen;635 19.4.4;Autoantibody;636 19.4.5;Clinical utility;637 19.4.6;Take-home messages;639 19.4.7;References;639 19.5;Chapter 74 Autoantibodies in the LambertEaton Myasthenic Syndrome (LEMS) and Amyotrophic Lateral Sclerosis (ALS);640 19.5.1;Abstract;640 19.5.2;Historical notes;641 19.5.3;The LambertEaton myasthenic syndrome;641 19.5.4;Amyotrophic lateral sclerosis;641 19.5.5;Autoantigen: Voltage-gated calcium channels;642 19.5.6;Autoantibody;642 19.5.7;Clinical utility;643 19.5.8;Take-home messages;645 19.5.9;References;645 19.6;Chapter 75 Ganglioside Autoantibodies;646 19.6.1;Abstract;646 19.6.2;Historical notes;646 19.6.3;The autoantigen(s);647 19.6.4;Autoantibodies;648 19.6.5;Clinical utility;651 19.6.6;Take-home messages;652 19.6.7;References;653 19.7;Chapter 76 Myelin Associated Antibodies: Myelin-Associated Glycoprotein Autoantibodies, Myelin Basic Protein Autoantibodies and Myelin...;654 19.7.1;Abstract;654 19.7.2;Myelin-associated glycoprotein;655 19.
7.3;Myelin basic protein and proteolipid protein;656 19.7.4;Conclusions;659 19.7.5;References;660 19.8;Chapter 77 Paraneoplastic Neurological Antibodies: Nuclear;662 19.8.1;Abstract;662 19.8.2;Historical notes;663 19.8.3;Autoantigens;663 19.8.4;Autoantibodies;664 19.8.5;Clinical utility;668 19.8.6;Take-home messages;669 19.8.7;References;670 19.9;Chapter 78 Paraneoplastic Neurological Antibodies: Purkinje Cell Cytoplasm;672 19.9.1;Abstract;672 19.9.2;Historical notes;673 19.9.3;Autoantigens;673 19.9.4;Autoantibodies;674 19.9.5;Clinical utility;676 19.9.6;Take-home messages;677 19.9.7;References;677 19.10;Chapter 79 Paraneoplastic Neurological Antibodies: Additional Reactivities;680 19.10.1;Abstract;680 19.10.2;Historical notes;681 19.10.3;Autoantigens;681 19.10.4;Autoantibodies;682 19.10.5;Clinical utility;685 19.10.6;Take-home messages;687 19.10.7;References;687 19.11;Chapter 80 Retinal Autoantibodies;688 19.11.1;Abstract;688 19.11.2;Historical notes;689 19.11.3;Autoantigen;689 19.11.4;Autoantibody;690 19.11.5;Clinical utility;692 19.11.6;Take-home messages;692 19.11.7;References;693 19.12;Chapter 81 Autoantibodies in Epilepsy;694 19.12.1;Abstract;694 19.12.2;Historical background;694 19.12.3;Voltage-gated potassium channel antibodies;695 19.12.4;Glutamic acid decarboxylase antibodies;696 19.12.5;Other autoantibodies in epilepsy;698 19.12.6;Conclusions;699 19.12.7;Take-home messages;699 19.12.8;References;699 20;Part XII Rheumatic Disease Autoantibodies;702 20.1;Chapter 82 Anti-Fodrin Antibodies;704 20.1.1;Abstract;704 20.1.2;Autoantigen;704 20.1.3;Autoantibody;705 20.1.4;Clinical utility;706 20.1.5;Take-home messages;709 20.1.6;References;709 20.2;Chapter 83 Antibodies to Laminin;710 20.2.1;Abstract;710 20.2.2;Historical notes;710 20.2.3;Autoantigen;711 20.2.4;Autoantibody;712 20.2.5;Clinical utility;713 20.2.6;Take-home messages;714 20.2.7;References;715 20.3;Chapter 84 Autoantibodies Against Muscarinic Acetylcholine Receptor in Patients with Sjögrens Syndrome;71
6 20.3.1;Abstract;716 20.3.2;Historical notes;717 20.3.3;Autoantigen;717 20.3.4;Autoantibody;717 20.3.5;Clinical utility;718 20.3.6;Take-home messages;719 20.3.7;References;719 20.4;Chapter 85 Beta2-Glycoprotein I Autoantibodies;722 20.4.1;Abstract;722 20.4.2;Historical notes;723 20.4.3;The Autoantigen;723 20.4.4;The autoantibodies;724 20.4.5;Clinical utility;726 20.4.6;Take-home messages;727 20.4.7;References;727 20.5;Chapter 86 C1 Inhibitor Autoantibodies;730 20.5.1;Abstract;730 20.5.2;Historical notes;730 20.5.3;The Autoantigen;731 20.5.4;The autoantibody;732 20.5.5;Clinical utility;733 20.5.6;Take-home messages;735 20.5.7;References;735 20.6;Chapter 87 Autoantibodies to C1q;738 20.6.1;Abstract;738 20.6.2;Historical notes;738 20.6.3;Autoantigen;739 20.6.4;Autoantibody;741 20.6.5;Clinical utility;742 20.6.6;Conclusions;745 20.6.7;Take-home messages;745 20.6.8;References;746 20.7;Chapter 88 Anti-Collagen Antibodies;748 20.7.1;Abstract;748 20.7.2;Historical notes;748 20.7.3;Collagen as an autoantigen;749 20.7.4;Autoantibody;751 20.7.5;Clinical utility;752 20.7.6;Take-home messages;753 20.7.7;References;753 20.8;Chapter 89 Anti-Cyclic Citrullinated Peptide Antibody;756 20.8.1;Historical perspective;756 20.8.2;Antibody/antigen;756 20.8.3;Summary;758 20.8.4;References;758 20.9;Chapter 90 Anti-Endothelial Cell Autoantibodies;760 20.9.1;Abstract;760 20.9.2;Historical notes;761 20.9.3;Autoantigens;761 20.9.4;Autoantibodies;763 20.9.5;Clinical utility;765 20.9.6;Take-home messages;766 20.9.7;References;766 20.10;Chapter 91 Lupus Anticoagulant Testing;768 20.10.1;Abstract;768 20.10.2;Historical notes;769 20.10.3;Autoantigen;769 20.10.4;Autoantibody;770 20.10.5;Clinical utility;771 20.10.6;Take-home messages;773 20.10.7;References;773 20.11;Chapter 92 Anticardiolipin Antibodies;776 20.11.1;Abstract;776 20.11.2;Historical notes;776 20.11.3;Autoantigens;777 20.11.4;Autoantibodies;777 20.11.5;Clinical utility;779 20.11.6;Take-home messages;780 20.11.7;References;780 20.12;Chapt
er 93 Phospholipid Autoantibodies (Non-Anticardiolipin)Anti-Prothrombin Antibodies;782 20.12.1;Abstract;782 20.12.2;Historical notes;782 20.12.3;Detection methods and immunological properties;783 20.12.4;Epitope mapping;784 20.12.5;Mechanisms of action;784 20.12.6;Pathophysiology of thrombosis and miscarriage;785 20.12.7;Clinical relevance;785 20.12.8;Treatment;786 20.12.9;Take-home messages;787 20.12.10;References;787 20.13;Chapter 94 Rheumatoid Factors;790 20.13.1;Abstract;790 20.13.2;Historical notes;790 20.13.3;Autoantigen;791 20.13.4;Autoantibodies;792 20.13.5;Clinical utility;795 20.13.6;Take-home messages;797 20.13.7;References;797 21;Part XIII Skin Disease Autoantibodies;798 21.1;Chapter 95 Autoantibodies to Mucocutaneous Antigens;800 21.1.1;Abstract;800 21.1.2;Historical notes;801 21.1.3;Type II Mucocutaneous autoimmunity: Epidermal antigens;803 21.1.4;Type II Mucocutaneous autoimmunity: Dermal antigens;809 21.1.5;Conclusion;812 21.1.6;Take-home messages;812 21.1.7;Acknowledgment;813 21.1.8;References;813 22;Part XIV Unique Clinical Situations;816 22.1;Chapter 96 Autoimmunity and the Newer Biopharmaceuticals;818 22.1.1;Abstract;818 22.1.2;Introduction;819 22.1.3;Toxicity profile and autoimmunity;820 22.1.4;Antinuclear, anti-dsDNA and anti-phospholipid antibodies;821 22.1.5;Possible mechanisms involved in the production of neutralising and non-neutralising autoantibodies during anti-TNF-alpha treatment;823 22.1.6;Conclusions;825 22.1.7;References;825 22.2;Chapter 97 Autoantibodies Against Tumor Suppressor Proteins;828 22.2.1;Abstract;828 22.2.2;Historical notes;829 22.2.3;Retinoblastoma (RB) gene;829 22.2.4;p16 gene;830 22.2.5;p73 gene;831 22.2.6;Conclusion;832 22.2.7;References;833 22.3;Chapter 98 Detection of Autoantibodies Using Protein Arrays;834 22.3.1;Abstract;834 22.3.2;Introduction;834 22.3.3;Early history;835 22.3.4;Preparation and optimal utilization of protein arrays;836 22.3.5;Application of protein arrays to autoimmunity;837 22.3.6;Protein array
s and proteomics;839 22.3.7;Conclusion;840 22.3.8;References;840 22.4;Chapter 99 Autoantibodies and Pregnancy Loss;844 22.4.1;Abstract;844 22.4.2;Historical notes;844 22.4.3;Autoantigens;845 22.4.4;Autoantibodies;845 22.4.5;Clinical utility;847 22.4.6;References;848 23;Part XV Future Directions;850 23.1;Chapter 100 Anti-Glycan Antibodies;852 23.1.1;Abstract;852 23.1.2;Glycan antigens;853 23.1.3;Anti-glycan antibodies in normal population;853 23.1.4;Anti-glycan antibodies in multiple sclerosis;854 23.1.5;Anti-glycan antibodies in inflammatory bowel disease;855 23.1.6;Take-home messages;856 23.1.7;References;857 23.2;Chapter 101 Future Trends;858 23.2.1;Abstract;858 23.2.2;The past;858 23.2.3;The Present;859 23.2.4;The Future;859 23.2.5;Take-home messages;860 23.2.6;References;860 24;Index;862 25;Color Plates;874


Technik

Dieses eBook wird im epub-Format geliefert und ist mit einem Adobe DRM-Kopierschutz versehen. Sie können dieses eBook auf vielen gängigen Endgeräten lesen.

Sie können dieses eBook auf vielen gängigen Endgeräten lesen.

Für welche Geräte?
Sie können das eBook auf allen Lesegeräten, in Apps und in Lesesoftware öffnen, die epub und Adobe DRM unterstützen:

  • tolino Reader
    Öffnen Sie das eBook nach der automatischen Synchronisation auf dem Reader oder übertragen Sie das eBook auf Ihr tolino Gerät mit einer kostenlosen Software wie beispielsweise Adobe Digital Editions.

  • Sony Reader und andere eBook Reader
    Laden Sie das eBook direkt auf dem Reader im eBook.de-Shop herunter oder übertragen Sie das eBook mit der kostenlosen Software Sony READER FOR PC/Mac oder Adobe Digital Editions auf ein Standard-Lesegeräte mit epub- und Adobe DRM-Unterstützung.

  • Tablets und Smartphones
    Installieren Sie die eBook.de READER App für Android und iOS oder verwenden Sie eine andere Lese-App für epub-eBooks mit Adobe DRM.

  • PC und Mac
    Lesen Sie das eBook direkt nach dem Herunterladen über "Jetzt lesen" im Browser, oder mit der kostenlosen Lesesoftware Adobe Digital Editions.

Schalten Sie das eBook mit Ihrer persönlichen Adobe ID auf bis zu sechs Geräten gleichzeitig frei.

Bitte beachten Sie: Dieses eBook ist nicht auf Kindle-Geräten lesbar.

Ihr erstes eBook?
Hier erhalten Sie alle Informationen rund um die digitalen Bücher für Neueinsteiger.

EAN: 9780080467238
Untertitel: 200:Adobe eBook. Sprache: Englisch.
Verlag: Elsevier Science
Erscheinungsdatum: Oktober 2011
Seitenanzahl: 872 Seiten
Format: epub eBook
Kopierschutz: Adobe DRM
Es gibt zu diesem Artikel noch keine Bewertungen.Kundenbewertung schreiben